BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down 5.9% on Monday . The stock traded as low as $2.39 and last traded at $2.40, with a volume of 349,213 shares traded. The stock had previously closed at $2.55.

Several equities research analysts recently weighed in on BDSI shares. FBR & Co boosted their price target on shares of BioDelivery Sciences International from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 4th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a research report on Friday, May 6th. Cantor Fitzgerald cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and reduced their price target for the stock from $9.00 to $5.00 in a research report on Wednesday, May 11th. Piper Jaffray Cos. restated an “overweight” rating and issued a $4.00 price target (down previously from $6.00) on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. Finally, Janney Montgomery Scott restated a “hold” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a research report on Tuesday, July 12th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $8.25.

The firm’s 50-day moving average price is $2.43 and its 200-day moving average price is $3.03. The stock’s market cap is $126.48 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. During the same quarter last year, the business earned ($0.16) EPS. The firm earned $3 million during the quarter, compared to analysts’ expectations of $2.96 million. BioDelivery Sciences International’s quarterly revenue was down 77.1% on a year-over-year basis. On average, equities analysts expect that BioDelivery Sciences International Inc. will post ($1.17) EPS for the current fiscal year.

Other hedge funds and institutional investors have made changes to their positions in the company. Sei Investments Co. raised its position in shares of BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares during the period. 1492 Capital Management LLC raised its position in shares of BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares during the period. Bank of Montreal Can raised its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the period. Finally, Royce & Associates LLC raised its position in shares of BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock worth $7,127,000 after buying an additional 87,200 shares during the period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.